Biomedical papers, 2010 (vol. 154), issue 3

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2010, 154(3):203-210 | 10.5507/bp.2010.031

ORAL ANTIPLATELET THERAPY IN STROKE PREVENTION. MINIREVIEW

Michal Krala, Roman Herziga, Daniel Sanaka, David Skoloudika, Ivanka Vlachovaa, Andrea Bartkovaa, Petr Hlustika, Michal Kovacikb, Petr Kanovskya
a Stroke Center, Department of Neurology, Faculty of Medicine and Dentistry, Palacky University and University Hospital, Olomouc, Czech Republic
b Department of Neurology, Central Military Hospital, Ruzomberok, Slovakia

Background: Antiplatelet therapy plays a crucial role in the primary and secondary prevention of noncardioembolic ischemic stroke / transient ischemic attacks (IS/TIA). Several antiplatelet agents are available. This review deals with the characteristics of particular antiplatelet agents as well as choice of antiplatelet treatment in various situations, based on the evidence and international recommendations.

Methods: PubMed and Stroke Trials Registry on-line databases and the European Stroke Organisation Guidelines for Management of IS/TIA 2008 and update of the recommendations of the American Heart Association / American Stroke Association Council 2008 on Stroke were used.

Results: Acetylsalicylic acid (ASA) is the only antiplatelet drug used in primary prevention, mainly to reduce the risk of myocardial infarction (MI), but also in women aged 45 years or more and in some patients with non-valvular atrial fibrillation to reduce risk of IS/TIA. In the secondary prevention of noncardioembolic IS/TIA, ASA in combination with long release dipyridamole (DIP) and clopidogrel (CLOP) alone are considered first choice therapies. The choice of the particular antiplatelet agent should be individualized according to the patient risk factor profiles and treatment tolerance. ASA alone or triflusal can be used alternatively in patients who cannot be treated with either ASA+DIP or CLOP. The use of indobufen should be considered only in patients in need of temporary interruption of the antiplatelet therapy. Ticlopidine (TIC) should not be newly introduced into the treatment. Currently, insufficient data are available on the use of cilostazol in IS/TIA prevention.

Keywords: Antiplatelet therapy, Ischemic stroke, Prevention

Received: February 15, 2010; Accepted: June 30, 2010; Published: September 1, 2010


References

  1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367:17471757. Go to original source... Go to PubMed...
  2. Rothwell PM, Coull AJ, Silver LE, Fairhead JF, Giles MF, Lovelock CE et al. Population-based study of eventrate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366:17731783. Go to original source...
  3. OBrien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L et al. Vascular cognitive impairment. Lancet Neurol 2003; 2:8998. Go to original source...
  4. Brainin M, Bornstein N, Boysen G, Demarin V. Acute neurological stroke care in Europe: results of the European Stroke Care Inventory. Eur J Neurol 2000; 7:510. Go to original source... Go to PubMed...
  5. Albers GW, Amarenco P, Easton JD, Sacco RL, Teal P. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Konference on Antitrombotic and Thrombolytic Therapy. Chest 2004; 126:483S -512S. Go to original source... Go to PubMed...
  6. Kistler JP et al. Cerebral embolism. Compr Ther 1996; 22:515530. Go to PubMed...
  7. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR et al. Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989; 25:382390. Go to original source... Go to PubMed...
  8. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL et al. Warfarin-Aspirin Recurrent Stroke Study Group (WARSS): A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345(20):144451. Go to original source... Go to PubMed...
  9. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group: A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42(6):85765.
  10. European Stroke Organisation (ESO) Executive Committee et al. Guidelines for Management of Ischaemic Stroke and Transient Ischaemic Attack 2008, Cerebrovasc Dis 2008; 25:457507.
  11. Adams RJ, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB et al.; American Heart Association; American Stroke Association. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2008; 39(5):164752. Go to original source... Go to PubMed...
  12. de Gaetano G, Collaborative Group of the Primary Prevention Project. Low-Dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 2001; 357(9250):8995.
  13. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352:12931304. Go to original source... Go to PubMed...
  14. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomized Trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988; 296(6618):3136. Go to original source... Go to PubMed...
  15. Steering Committee of the Physicians Health Study Research Group. Final Report on the aspirin component of the ongoing Physicians Health Study. N Engl J Med 1989; 321:129135.
  16. ETDRS Investigators. Aspirin effects on mortality and mor bidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992; 268(10):1292300.
  17. Hansson L, Yanchetti A, Carruthers S, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood pressure lowering and low/dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351(9118):175562. Go to original source... Go to PubMed...
  18. Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:10441054. Go to original source... Go to PubMed...
  19. The Dutch TIA Study Group. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 1991; 325:1261 1266. Go to original source... Go to PubMed...
  20. Anthithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:7186.
  21. He J, Whelton PK, Vu B, Klag MJ. Aspirin and risk of hemorrhagic stroke. A meta-analysis of randomised controlled trials. JAMA 1998: 280:19305. Go to original source... Go to PubMed...
  22. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:113. Go to original source... Go to PubMed...
  23. De Schryver EL, Algra A, van Gijn J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev 2006; (2):CD001820. Review. Go to original source...
  24. ESPRIT Study Group, Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367(9523):166573.
  25. Diener HC, Sacco R, Yusuf S, Steering Committee; PRoFESS Study Group: Rationale, design and baseline data in a randomized, double-blind, controlled trial comparing two antithrombotic regimes (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regime for Effectively Avoiding Second Strokes Trial (PRoFESS). Cerebrovasc Dis 2007; 23:368 80. Go to original source... Go to PubMed...
  26. Hass WK, Easton ID, Adams HP Jr, Ticlopidine aspirin stroke study group (TASS). A randomized Trial comparing ticlopidine hydrochloride with aspirin for the prevention of of stroke in highrisk patients. N Engl J Med 1989; 321:5017. Go to original source... Go to PubMed...
  27. Gent M, Blakely JA, Easton ID. The Canadian American Ticlopidine Study (CATS) in thrombembolic stroke. Lancet 1989; 1(8649):121520. Go to original source... Go to PubMed...
  28. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348(9038):132939.
  29. Ringleb PA, Bhatt DL, Hirsch AT, Topol EJ, Hacke W. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke 2004; 35:52832. Go to original source... Go to PubMed...
  30. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345(20):1506. Go to original source...
  31. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebocontrolled trial. Lancet 2004; 364(9431):3317. Go to original source... Go to PubMed...
  32. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:170617. Go to original source... Go to PubMed...
  33. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the. PCI-CURE study. 2001; 358(9281):527 33.
  34. Beinart SC, Kolm P, Veledar E, Zhang Z, Mahoney EM, Bouin O, et al. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol 2005; 46(5):7619. Go to original source... Go to PubMed...
  35. McKevitt FM, Randall MS, Cleveland TJ, Gaines PA, Tan KT, Venables GS. The benefits of combined anti-platelet treatment in carotid artery stenting. Eur J Vasc Endovasc Surg 2005; 29(5):5227. Go to original source... Go to PubMed...
  36. Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) Trial. Circulation 2005; 111:223340. Go to original source... Go to PubMed...
  37. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004; 109:147681. Go to original source... Go to PubMed...
  38. Cataldo G, Braga M, Pirotta N, Lavezzari M, Rovelli F, Marubini E. Factors influencing 1-year patency of coronary artery saphenous vein grafts. Studio Indobufene nel Bypass Aortocoronarico (SINBA). Circulation 1993; 88(5 Pt 2):II938. Go to PubMed...
  39. Bergamasco B, Benna P, Carolei A, Rasura M, Rudelli G, Fieschi C. A randomized trial comparing ticlopidine hydrochloride with indobufen for the prevention of stroke in high-risk patients (TISS Study). Ticlopidine Indobufen Stroke Study. Funct Neurol 1997; 12(1):3343. Go to PubMed...
  40. Culebras A, Rotta-Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, et al. Triflusal vs aspirin for prevention of cerebral in farction: a randomized stroke study. Neurology 2004; 62(7):1073 80. Go to original source... Go to PubMed...
  41. Matias-Guiu J, Ferro JM, Alvarez-Sabin J, Torres F, Jimenez MD, Lago A, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34(4):8408. Go to original source... Go to PubMed...
  42. Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6(4):3340. Go to original source... Go to PubMed...